ID

36430

Descripción

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT02392455 Brief Summary: This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.

Link

https://clinicaltrials.gov/show/NCT02392455

Palabras clave

Versiones (2)
  1. 15/1/19 15/1/19 -
  2. 14/5/19 14/5/19 -
Titular de derechos de autor

GSK group of companies

Subido en

14 de mayo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Vargatef 2nd line therapy in NSCLC NCT02392455

Inglés

Eligibility Criteria

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Criteria
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
Is the participant 18 or older?
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
Does the participant have locally advanced, metastastic and/or recurrent NSCLC with adenocarcinoma histology for which vargatef treatment is indicated according to Summary of Product Characteristics (SmPC)?
Descripción

The participant should have locally advanced, metastastic and/or recurrent NSCLC with adenocarcinoma histology for which vargatef treatment is indicated according to Summary of Product Characteristics (SmPC)

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0677984
UMLS CUI [1,3]
C2939420
UMLS CUI [1,4]
C2945760
UMLS CUI [1,5]
C0344441
UMLS CUI [1,6]
C0001418
UMLS CUI [1,7]
C2700098
UMLS CUI [1,8]
C3146298
UMLS CUI [1,9]
C0332290
UMLS CUI [1,10]
C1709515
Does the participant have had first line therapy but not yet started second-line therapy?
Descripción

The participant should have had first line therapy but not yet started second-line therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1444637
UMLS CUI [1,2]
C1708063
UMLS CUI [2,1]
C1444646
UMLS CUI [2,2]
C1710038
Are standard 21-day-cycles docetaxel treatment according to smpc possible with the participant?
Descripción

Standard 21-day-cycles docetaxel treatment according to smpc should be possible

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0246415
UMLS CUI [1,2]
C0332149
UMLS CUI [1,3]
C0332290
UMLS CUI [1,4]
C1709515
Did the participant give written informed consent?
Descripción

Informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
Are there contraindications according to the smpc of vargatef or docetaxel for the participant?
Descripción

Drug contraindications

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C2700098
UMLS CUI [1,3]
C1709515
UMLS CUI [2,1]
C0522473
UMLS CUI [2,2]
C0246415
UMLS CUI [2,3]
C1709515
Were there more than one systemic therapy for treatment of NSCLC in a palliative setting?
Descripción

Palliative systemic therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0332152
UMLS CUI [1,3]
C0007131
UMLS CUI [1,4]
C0597023
UMLS CUI [1,5]
C0439064
Is the participant currently partcipating in another non-interventional study or a clinical trial?
Descripción

Study enrollment status

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0521116
UMLS CUI [1,3]
C0008976
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C1516879
UMLS CUI [2,3]
C4684718
Is the participant pregnant?
Descripción

Pregnancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
Is the participant breastfeeding?
Descripción

Breast feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006147
Volver a la parte superior de la página

Similar models

Eligibility Criteria

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Criteria
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
Is the participant 18 or older?
boolean
C0001779 (UMLS CUI [1])
NSCLC
Item
Does the participant have locally advanced, metastastic and/or recurrent NSCLC with adenocarcinoma histology for which vargatef treatment is indicated according to Summary of Product Characteristics (SmPC)?
boolean
C0007131 (UMLS CUI [1,1])
C0677984 (UMLS CUI [1,2])
C2939420 (UMLS CUI [1,3])
C2945760 (UMLS CUI [1,4])
C0344441 (UMLS CUI [1,5])
C0001418 (UMLS CUI [1,6])
C2700098 (UMLS CUI [1,7])
C3146298 (UMLS CUI [1,8])
C0332290 (UMLS CUI [1,9])
C1709515 (UMLS CUI [1,10])
Treatment Status
Item
Does the participant have had first line therapy but not yet started second-line therapy?
boolean
C1444637 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
C1444646 (UMLS CUI [2,1])
C1710038 (UMLS CUI [2,2])
Docetaxel possible
Item
Are standard 21-day-cycles docetaxel treatment according to smpc possible with the participant?
boolean
C0246415 (UMLS CUI [1,1])
C0332149 (UMLS CUI [1,2])
C0332290 (UMLS CUI [1,3])
C1709515 (UMLS CUI [1,4])
Informed consent
Item
Did the participant give written informed consent?
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Drug contraindications
Item
Are there contraindications according to the smpc of vargatef or docetaxel for the participant?
boolean
C0522473 (UMLS CUI [1,1])
C2700098 (UMLS CUI [1,2])
C1709515 (UMLS CUI [1,3])
C0522473 (UMLS CUI [2,1])
C0246415 (UMLS CUI [2,2])
C1709515 (UMLS CUI [2,3])
Palliative systemic therapy
Item
Were there more than one systemic therapy for treatment of NSCLC in a palliative setting?
boolean
C1515119 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0007131 (UMLS CUI [1,3])
C0597023 (UMLS CUI [1,4])
C0439064 (UMLS CUI [1,5])
Study enrollment status
Item
Is the participant currently partcipating in another non-interventional study or a clinical trial?
boolean
C2348568 (UMLS CUI [1,1])
C0521116 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C2348568 (UMLS CUI [2,1])
C1516879 (UMLS CUI [2,2])
C4684718 (UMLS CUI [2,3])
Pregnancy
Item
Is the participant pregnant?
boolean
C0032961 (UMLS CUI [1])
Breast feeding
Item
Is the participant breastfeeding?
boolean
C0006147 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial